BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 11, 2004
View Archived Issues
Amgen Starting Phase III Trials With Treatment For Bone Loss
As promised, Amgen Inc. began dosing patients in two pivotal Phase III trials of AMG 162, its fully human monoclonal antibody designed to treat post-menopausal osteoporosis (PMO) and treatment-induced bone loss. (BioWorld Today)
Read More
Pharmasset Raises $40M In Series D For HIV Candidates
Read More
Bioenvision Begins Pivotal Trial Of Clofarabine For AML In Europe
Read More
QLT Enlists Array To Assist With Work On Cancer Targets
Read More
Brain Research Firm Neurome Buys Digital Gene Technologies
Read More
Other News To Note
Read More
Appointments And Advancements
Read More